John Roberts
Cancer Genetics has appointed John Roberts as CEO and president. Roberts had been serving as interim CEO since February, in addition to serving as chief operating officer and executive VP of finance, positions he has held since July 2016. Roberts served as CFO for VirMedica from August 2015 to June 2016. Prior to VirMedica, Roberts served as chief financial and administrative officer for AdvantEdge Healthcare Solutions, CFO and treasurer for InfoLogix, and as CFO at public medical device and healthcare firms including Clarient and Daou Systems.
Maneesh Arora
Exact Sciences Chief Operating Officer Maneesh Arora will be leaving the company at the end of the year. During a conference call with analysts following the release of the company's first quarter earnings, Exact CEO Kevin Conroy announced that Arora "will transition to a life outside of Exact Sciences," adding that he will spend the rest of 2018 "focusing his operational and strategic rigor on the priority of advancing our pipeline plans to fuel our future success." The company does not anticipate finding a replacement COO at this time, Conroy noted.
Alberto Mas, Patrick Kaltenbach, Bill Tozzi
Becton Dickinson has announced three executive leadership changes. Alberto Mas will now lead the firm's medical segment; Patrick Kaltenbach will head up life sciences, replacing Mas, effective May 29; and Bill Tozzi will lead the firm's interventional segment on an interim basis.
Mas was head of BD's life sciences business for two years, and previously served as president of three of the firm's other major business units. Kaltenbach previously served as senior vice president of life sciences and applied markets at Agilent. Tozzi had been serving as the integration leader for the CR Bard transaction since April 2017, and prior to that was the president of the firm's medication delivery solutions division for six years. Tozzi will replace John Groetelaars, who served as the president of the interventional segment since the completion of the Bard transaction and who has decided to leave BD for an executive position at another company.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.